Skip to main content

Table 3 Treatment withdrawal and seizure freedom rates (Kaplan-Meier estimates) for sodium valproate and carbamazepine strata (intent-to-treat population)a

From: Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study

Sodium valproate stratum LEV VPA-ER
All seizure types n = 48 All seizure types n = 52
Generalized seizures only n = 14 Generalized seizures only n = 22
Treatment withdrawal rate, % (95 % CI)
 6 months All seizure types 4.2 (1.1–15.7) 19.2 (10.8–32.8)
Generalized seizures only 7.1 (1.0–40.9) 18.2 (7.2–41.5)
 12 months All seizure types 10.4 (4.5–23.2) 23.1 (13.8–37.0)
Generalized seizures only 14.3 (3.8–46.1) 22.7 (10.2–46.3)
Seizure freedom rate, % (95 % CI)
 6 months All seizure types 70.4 (55.1–81.3) 63.4 (47.8–75.4)
Generalized seizures only 69.6 (37.8–87.4) 63.3 (38.1–80.6)
 12 months All seizure types 66.0 (50.5–77.6) 59.0 (43.5–71.6)
Generalized seizures only 52.8 (28.9–72.0)
Carbamazepine stratum LEV CBZ-CR
All seizure types n = 104 All seizure types n = 103
Focal seizures only n = 93 Focal seizures only n = 94
Treatment withdrawal rate, % (95 % CI)
 6 months All seizure types 19.2 (12.9–28.2) 41.8 (32.9–51.9)
Focal seizures only 18.3 (11.8–27.8) 40.4 (31.3–51.1)
 12 months All seizure types 25.0 (17.8–34.5) 46.6 (37.6–56.7)
Focal seizures only 24.7 (17.2–34.8) 45.8 (36.4–56.4)
Seizure freedom rate, % (95 % CI)
 6 months All seizure types 63.3 (52.6–72.1) 63.2 (51.4–72.8)
Focal seizures only 59.3 (48.0–68.9) 63.1 (51.0–73.1)
 12 months All seizure types 59.8 (49.1–69.0) 59.8 (47.7–69.9)
Focal seizures only 55.5 (44.2–65.4) 61.3 (49.0–71.5)
  1. Abbreviations: CBZ-CR controlled-release carbamazepine, CI confidence interval, LEV levetiracetam, VPA-ER extended-release sodium valproate
  2. aFor the sodium valproate stratum, data are presented for all patients (intent-to-treat population excluding unclassified seizure types) and those with generalized seizures only (intent-to-treat population excluding unclassified, unknown and mixed seizure types). For the carbamazepine stratum, data are presented for all patients (intent-to-treat population excluding unclassified seizure types) and those with focal seizures only (intent-to-treat population excluding unclassified, unknown and mixed seizure types)